Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGEN2373 + Balstilimab + Cyclophosphamide + GVAX |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGEN2373 | AGEN-2373|AGEN 2373 | TNFRSF9 Antibody 32 | AGEN2373 is a antibody that targets CD137 and acts as an agonist, resulting in increased CD137 signaling and potentially leading to enhanced anti-tumor immune response (Journal of Clinical Oncology 2019 37:15_suppl, e14005). | |
Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 123 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). | |
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
GVAX | GVAX is a cancer vaccine derived from irradiated autologous or allogeneic tumor cells engineered to secrete GM-CSF, which potentially stimulates anti-tumor immune response (PMID: 16026242). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06782932 | Phase Ib/II | AGEN2373 + Balstilimab + Pooled Mutant KRAS-Targeted Long Peptide Vaccine AGEN2373 + Balstilimab + Cyclophosphamide + GVAX | Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer | Not yet recruiting | USA | 0 |